Brief: Abbisko Cayman Says US FDA Grants Rare Pediatric Disease Designation For FGFR2/3 Inhibitor ABSK061
11/03/2026 24:49
March 11 (Reuters) - Abbisko Cayman Ltd 2256.HK: US FDA GRANTS RARE PEDIATRIC DISEASE DESIGNATION FOR FGFR2/3 INHIBITOR ABSK061 Further company coverage: 2256.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration